S&P Futures
4,029.75 +28.50 (+0.71%) Dow Futures
32,662.00 +228.00 (+0.70%) Nasdaq Futures
12,938.00 +47.75 (+0.37%) Russell 2000 Futures
1,768.70 +21.00 (+1.20%) Crude Oil
70.13 +0.87 (+1.26%) Gold
1,954.00 -29.80 (-1.50%)
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 1.2750 |
| Open | 1.2800 |
| Bid | 1.2600 x 800 |
| Ask | 1.4000 x 800 |
| Day's Range | 1.2200 - 1.3000 |
| 52 Week Range | 1.2100 - 126.2600 |
| Volume | |
| Avg. Volume | 484,841 |
| Market Cap | 17.045M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has entered a research agreement with Georgetown University focused on the evaluation of the Company's lead HDAC6 inhibitor candidate, SP-2-225, evaluating the anti-tumor effect of the combination of SP-2-225 and RT in a syngeneic breast cancer model. The pre-clinical
- PR Newswire
Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today provided a corporate update in connection with the filing of its Annual Report on Form 10-K for the year ended December 31, 2022.
- PR Newswire
Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced it has signed an agreement with the University of Iowa (UI) Pharmaceuticals for formulation development and clinical batch manufacture of drug capsules of Ropidoxuridine. This is expected to be the final step required in the drug manufacturing process for use in Shuttle P
